When was Istari Oncology founded?

Istari Oncology was founded in 2014 and raised its 1st funding round 3 years after it was founded.

Where is Istari Oncology located?

Istari Oncology is headquartered in Durham, United States. It is registered at 430 Davis Dr Suite 560 Morrisville, NC 27560.

How many employees does Istari Oncology have?

As of Dec 31, 2021, Istari Oncology has 47 employees, reflecting a 35% year-over-year growth in headcount.

Is Istari Oncology a funded company?

Istari Oncology is a funded company, having raised a total of $48.6M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 13, 2017.

When was the latest funding round of Istari Oncology?

Istari Oncology's latest funding was a $***** Series B round on Apr 19, 2021, with participation from 0 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $684M in funding in 2026 to date.

Where does Istari Oncology rank among its competitors?

Istari Oncology ranks 939th amongst 3447 active competitors, of which 1159 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Istari Oncology?

Istari Oncology's top competitors include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Istari Oncology - 2026 Company Profile, Team, Funding & Competitors

Istari Oncology is a series B company based in Durham (United States), founded in 2014 by Darell Bigner and Matthias Gromeier. It operates as a Developer of viral vaccines and antibody drug conjugates for the treatment of cancer. Istari Oncology has raised $48.6M in funding. The company has 3447 active competitors, including 1159 funded and 824 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and Sana Biotechnology.

Company Details

Developer of viral vaccines and antibody-drug conjugates for the treatment of cancer. The company has two platforms in clinical development: Polio Virus Sabin-Rhinovirus Poliovirus (PVS-RIPO) and Antibody-Directed Immuno-Conjugates (ADC). Its drug pipeline includes PVS-RIPO, a viral vaccine for Glioblastoma (Phase 2), D2C7-IT, an ADC for Glioblastoma (Phase 1). PVS-RIP) is also being developed for breast and melanoma (Preclinical). The company has licensed its technology platforms from Duke University.

Website: istarioncology.com
Social
Email ID: *****@istarioncology.com
Phone Number: +1 **********
Registered Address: 430 Davis Dr Suite 560 Morrisville, NC 27560

Key Metrics

Founded Year

2014

Location

Durham, United States

Stage

Series B

Total Funding

$48.6M in 3 rounds

Latest Funding Round

Series B, Apr 19, 2021, $*****

Investors

Pappas Capital

Ranked

939^th among 3447 active competitors

Employee Count

47 as on Dec 31, 2021

Similar Companies

Jazz Pharmaceuticals & 3289 more

View Istari Oncology's full profile

Istari Oncology is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ISTARI ONCOLOGY, INC. CIN: 47-3350798 , United States, Active	Nov 19, 2018	-	47 (As on Dec 31, 2021)	-

Istari Oncology has raised a total funding of $48.6M over 3 rounds. Its first funding round was on Feb 13, 2017. Istari Oncology has 1 institutional investor.

Here is the list of recent funding rounds of Istari Oncology:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 19, 2021	7251725	Series B	8878843	7193623	3325601	9177181
May 25, 2017	6270337	Series A	8683623	7954347	2513466	4929485
Feb 13, 2017	5308889	Series A	6291908	7915323	7954040	2426482

Access funding benchmarks and valuations. Sign up today!

View details of Istari Oncology's funding rounds and investors

The founders of Istari Oncology are Darell Bigner and Matthias Gromeier.

Here are the details of Istari Oncology's key team members:

Darell Bigner: Founder of Istari Oncology.
Matthias Gromeier: Founder of Istari Oncology.

View details of Istari Oncology's Founder profiles and Board Members

Istari Oncology's employee count trend

Istari Oncology has 47 employees as of Dec 21. The total employee count is 34.0% more than what it was in Dec 20. Here is Istari Oncology's employee count trend over the years:

Employee count trend for Istari Oncology

Uncover Istari Oncology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Istari Oncology include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Here is the list of Top 10 competitors of Istari Oncology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
6th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Tamburi Investment Partners, Vivo Capital ... & 4 others	73/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
8th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
10th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
939th	Istari Oncology 2014, Durham (United States), Series B	Developer of viral vaccines and antibody drug conjugates for the treatment of cancer	$48.6M	Pappas Capital	43/100